Vitestro raises €12m in Series A financing
With assets of €12m through a Series A financing, Dutch Vitestro NV aims to bring the world's first autonomous blood drawing device to the market.
California-based Sonder Capital led the Series A financing round alongside existing investors and new private investors. According to Vitestro, the proceeds will be used to accelerate product development, prepare EU market authorisation, and initiate production of the robotic blood drawing device.
Autonomous blood drawing is closing the gap of of skilled healthcare workers in performing the billions of blood draws annually. Vitestro’s device combines AI-based, ultrasound-guided 3D reconstruction with robotic needle insertion, ensuring accurate and secure blood collection. A prototype has been tested on more than 1,000 patients. Clinical studies will continue in 2023, and European market introduction is anticipated in 2024.
adobe stock - Yanina 
Cytovation ASA
American Academy of Dermatology;doi.org/10.1016/j.jaad.2019.03.056